Screener
Indivior Pharmaceuticals, Inc. INDV Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $35 | $48 |
| Accrued employee-related obligations | 42 | 103 |
| Accrued indirect tax and government fees | 5 | 20 |
| Accruals for third-party services | 92 | 76 |
| Accrued other expenses | 4 | 3 |
| Total accounts payable and accrued expenses | $178 | $250 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s accounts payable?
- Indivior Pharmaceuticals, Inc. (INDV) reported accounts payable of $35M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s accounts payable changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s accounts payable decreased by 23.9% year-over-year, from $46M to $35M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s accounts payable?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s accounts payable has grown at a -50.4% compound annual growth rate (CAGR), from $195M to $48M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Indivior Pharmaceuticals, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude